In this episode of LifeSci Talks, Mark Wade, Global Practice Leader & COA SME at TransPerfect Life Sciences, is joined by Katja Rudell, VP of Patient-Centered Outcomes at Kielo Research, to take a behind-the-scenes look at the reality of patient-centered instrument development. They discuss diaries and quality of life tools, rare disease challenges, and proxy reporting, as well as the tradeoffs that can often occur in balancing regulatory rigor, patient burden, and realistic instrument usability. Listen in to hear why multiple instruments for the same disease can often create not only frustration for patients, but can also overburden them simultaneously. The episode will share suggestions as to how study teams can design smarter, more patient-centered measurement strategies.

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, sits down with Alice Biggane, Outcomes Innovation and Research Lead at Pfizer UK, to discuss how various PRO measures inform and impact reimbursement decisions for HTA driven markets. Together they unpack what data sources and methods exist for the quantification and understanding of HRQoL for cost-effectiveness decision making and the complex interplay between the need to reduce burden and increase transparency through standardization, while maintaining the crucial and nuanced balance of different stakeholder requirements. Tune in to learn how leading organizations are working to build more inclusive, efficient, and patient-focused clinical trials, and accelerating patient-access to new health technologies.

In this episode of LifeSci Talks, Mark Wade, Global Practice Leader at TransPerfect Life Sciences, is joined by Jonathan Norman, Director of Translation and Localization at YPrime, for an in-depth discussion on the realities of eCOA libraries. Together, they explore why “libraries” are more accurately described as asset repositories, the conditions under which reuse can meaningfully accelerate study timelines, and the limitations that prevent them from being a universal solution. The conversation highlights both the efficiencies and challenges of reuse, providing clarity on how sponsors and providers can better align expectations in clinical trial execution.